Q2 FY2026 · ended Jun 30, 2026 · Revenue $9.63M, +0.2% YoY · Filed Aug 6, 2026
Cytosorbents Corporation (CTSO) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $9.6 million and a net loss of $4.4 million. Free cash flow was -$597,000. As of Jun 30, 2026 it held $4.4 million in cash and investments and $29.4 million in total debt.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- CTSO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Princeton, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1175151
- Former names
- MedaSorb Technologies CORP (until Apr 15, 2010); GILDER ENTERPRISES INC (until Jul 24, 2006)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $9.6M | $8.9M | $9.2M | $9.5M | $9.6M |
| Operating income | -$2.6M | -$3.0M | -$4.4M | -$2.9M | -$3.6M |
| Net income | -$4.4M | -$5.1M | -$5.5M | -$3.2M | $1.9M |
| Diluted EPS | -$0.07 | -$0.08 | -$0.09 | -$0.05 | $0.03 |
| Operating cash flow | -$583,000 | -$1.2M | -$4.8M | -$2.6M | -$1.5M |
| Free cash flow | -$597,000 | -$1.2M | -$4.9M | -$2.6M | -$1.5M |
| Total assets | $38.0M | $40.6M | $44.2M | $45.8M | $48.0M |
| Total liabilities | $38.7M | $38.4M | $38.3M | $36.7M | $36.4M |
| Stockholders' equity | -$751,000 | $2.2M | $5.9M | $9.0M | $11.6M |
| Cash and investments | $4.4M | $4.8M | $6.2M | $7.5M | $10.2M |
| Total debt | $29.4M | $29.3M | $29.1M | $27.1M | $27.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 23, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Aug 14, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 7, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
All 977 Cytosorbents Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.